GLP-1 medications have also been associated with: Worsening of diabetic retinopathy Exacerbation of age-related macular degeneration Optic nerve complications, including NAION These risks dont mean you should stop taking your medication, but they do show why its important to have an eye exam before starting and regular follow-up exams while on treatment
If your concern is preventing nutritional deficiency and supporting general energy levels, B12 has the stronger case
Weight Management and Body Composition : Sustainable weight loss with possible preservation of lean muscle helps maintain healthier body composition over time
Subcutaneous semaglutide starts at 0.25mg once weekly and can be increased to up to 2.0mg once weekly following a dose escalation schedule if more glycemic control is needed [13]
doi: 10.1016/S0140-6736(21)00213-0 [DOI] [PubMed] [Google Scholar] 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al
The class of drugs which these lawsuits focus on are glucagon like peptide 1 receptor agonists (GLP-1RA)
